Physician profile
Anthony Amabile
NPI 1669445078
$8,540.12
in general payments reported to CMS, 2019-2025
38 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,786 · 2020: $1,129 · 2021: $549 · 2022: $668 · 2023: $630 · 2024: $1,201 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,837.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $966.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $931.71 | 2019-2025 | Jardiance |
| Amgen INC. | $923.47 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $546.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $463.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $427.64 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $277.61 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $236.83 | 2019-2022 | |
| Abbvie INC. | $219.23 | 2019-2025 | Vraylar, Qulipta |
| Abbott Laboratories | $198.21 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $140.58 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.22 | 2022 | |
| Glaxosmithkline, LLC. | $125.70 | 2019-2025 | Trelegy Ellipta |
| Dexcom, INC. | $102.38 | 2024-2025 | Dexcom G6 Transmitter |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $100.40 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $97.90 | 2019-2022 | |
| Corcept Therapeutics | $91.10 | 2019-2025 | Korlym |
| Eisai INC. | $76.17 | 2021-2025 | |
| Insulet Corporation | $75.52 | 2019-2023 | Omnipod |
| Merck Sharp & Dohme LLC | $69.60 | 2019-2025 | Capvaxive, Verquvo, Belsomra |
| Astellas Pharma US INC | $69.49 | 2019-2023 | Veozah |
| Esperion Therapeutics, INC. | $59.91 | 2021-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $53.71 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $53.17 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $43.80 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.16 | 2019-2020 | |
| Stryker Corporation | $25.98 | 2025 | Clottriever Bold Catheter |
| Otsuka America Pharmaceutical, INC. | $20.65 | 2022 | |
| Grifols USA, LLC | $18.55 | 2020 | |
| Antares Pharma, INC. | $18.36 | 2024 | Xyosted |
| Alnylam Pharmaceuticals INC. | $17.76 | 2025 | Givlaari |
| Cashflow Solutions, LLC | $16.40 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| E.R. Squibb & Sons, L.L.C. | $15.88 | 2019 | |
| Neotract INC. | $14.10 | 2019 | |
| Shire North American Group INC | $13.55 | 2019 | |
| Hikma Pharmaceuticals USA | $13.33 | 2020 | |
| Allergan, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Amabile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.